Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAM: Methylene Blue for Brain Dysfunction in Schizophrenia
NCT07866833Completed
- Sponsor
- King's College London
- Start
- Jun 2020
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Randomised trial of methylene blue in schizophrenia (2 arms), sponsored by King's College London. Primary endpoint: Functional Magnetic Resonance Imaging Blood-Oxygen-Level-Dependent response at Day 1. Started Jun 2020; status: completed.
02
Drugs
methylene blue
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07866833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07866833.